Diagrammatic representation of primer alignment on sodium bisulphite-treated p16 promoter sequence

<p><b>Copyright information:</b></p><p>Taken from "Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing"</p><p>Nucleic Acids Research 2006;34(11):e78-e78.</p><p>Published online 28 Jun 2006</p><p>PMCID:PMC1904102.</p><p>© 2006 The Author(s)</p> Cytosines in squares indicate the nucleotides interrogated by pyrosequencing in PMA and MEP assays (i.e. CpG dinucleotides). The T nucleotide in a square indicates the bisulphite control of these assays (site of non-CpG cytosine). MEP, methylation enrichment PCR primers; PMA, pyrosequencing methylation assay primers; PSEQ, pyrosequencing primer; MSP, methylation-specific PCR primers (primers specific for unmethylated target DNA contain T in squares; primers specific for methylated DNA target contain C in squares)

Agarose gels of PCR products following () p16 MSP, () p16 MEP, and () cyclin A1 MEP

<p><b>Copyright information:</b></p><p>Taken from "Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing"</p><p>Nucleic Acids Research 2006;34(11):e78-e78.</p><p>Published online 28 Jun 2006</p><p>PMCID:PMC1904102.</p><p>© 2006 The Author(s)</p> U, PCR using MSP primers specific for unmethylated DNA; M, PCR using methylation-specific MSP primers; A and B, two independent MEP assays. Rows 1–4 (top to bottom) correlate with rows 1–4 in dilution matrix ; i.e. row 1, no dilution of starting M:U concentrations; row 2, 1/10 dilutions, etc. Lanes 1–8 correlate with columns 1–8 in dilution matrix ; i.e. lane 1, M:U ratio of 1:1; lane 2, M:U ratio of 1:5, etc

Distribution of <i>CEL</i> VNTR lengths for alcoholic chronic pancreatitis (ACP) and alcoholic liver cirrhosis (ALC) patients from Germany.

<p>Distribution of <i>CEL</i> VNTR lengths for alcoholic chronic pancreatitis (ACP) and alcoholic liver cirrhosis (ALC) patients from Germany.</p

Distribution of <i>CEL</i> VNTR lengths for alcoholic liver cirrhosis (ALC) patients and controls from Germany.

<p>Distribution of <i>CEL</i> VNTR lengths for alcoholic liver cirrhosis (ALC) patients and controls from Germany.</p

Genotype distribution of <i>CEL</i> VNTR lengths for alcoholic liver cirrhosis (ALC) patients and controls from Germany.

<p>Genotype distribution of <i>CEL</i> VNTR lengths for alcoholic liver cirrhosis (ALC) patients and controls from Germany.</p

Distribution of <i>CEL</i> VNTR lengths for alcoholic chronic pancreatitis (ACP) patients and controls from the United Kingdom.

<p>Distribution of <i>CEL</i> VNTR lengths for alcoholic chronic pancreatitis (ACP) patients and controls from the United Kingdom.</p

Distribution of <i>CEL</i> VNTR lengths for alcoholic chronic pancreatitis (ACP) patients and controls from Germany.

<p>Distribution of <i>CEL</i> VNTR lengths for alcoholic chronic pancreatitis (ACP) patients and controls from Germany.</p

Genotype distribution of <i>CEL</i> VNTR lengths for alcoholic liver cirrhosis (ALC) patients and controls from the United Kingdom.

<p>Genotype distribution of <i>CEL</i> VNTR lengths for alcoholic liver cirrhosis (ALC) patients and controls from the United Kingdom.</p

Genotypes of observed <i>CEL</i> duplication alleles from Germany.

<p>Genotypes of observed <i>CEL</i> duplication alleles from Germany.</p

Genotypes of observed <i>CEL</i> duplication alleles from the United Kingdom.

<p>Genotypes of observed <i>CEL</i> duplication alleles from the United Kingdom.</p